SCHEDULE 13G/A 0001814554-25-000176 0001281446 XXXXXXXX LIVE 5 Common Shares, no par value per share 12/31/2025 0001374339 ProMIS Neurosciences Inc. 74346M505 Suite 200, 1920 Yonge Street Toronto, Ontario A6 M4S 3E2 Rule 13d-1(c) Great Point Partners, LLC DE 0.00 409648.00 0.00 409648.00 409648.00 N 9.99 IA OO Dr. Jeffrey R. Jay, M.D. X1 0.00 409648.00 0.00 409648.00 409648.00 N 9.99 HC IN Ms. Lillian Nordahl X1 0.00 409648.00 0.00 409648.00 409648.00 N 9.99 HC IN ProMIS Neurosciences Inc. Suite 200, 1920 Yonge Street, Toronto, Ontario M4S 3E2 Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated February 17, 2026, a copy of which is filed with this SCHEDULE 13G/A as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act. The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830 Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States. Y 409,648 9.99 0 409,648 0 409,648 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 2,391,294 shares outstanding, which is the sum of (i) 53,811,110 common shares outstanding as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025, but giving effect to the 1:25 reverse stock split effective November 28, 2025 reported by the Issuer in its Form 8-K filed on November 19, 2025, resulting in 2,152,444 post-split shares (ii) 238,894 shares of Common Stock issuable upon exercise of Warrants held by the reporting persons (subject to the Beneficial Ownership Cap and after giving effect to the same 1:25 reverse stock split). The reporting persons hold in the aggregate Pre-Funded Warrants to purchase 18,691 shares of Common Stock and Warrants to purchase 390,957 shares of Common Stock (together with the Pre-Funded Warrants referred to herein as the "Warrants"); however, the provisions of such Warrants restrict the exercise of such Warrants to the extent that, after giving effect to such exercise, the holder of the Warrants and its affiliates, together with any other person or entities with which such holder would constitute a group, would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Cap"). As a result, an aggregate of 238,894 shares underlying such Warrants are beneficially owned by the reporting persons. Biomedical Value Fund, L.P. ("BVF") is the record holder of Warrants to purchase 282,657 shares of Common Stock (the "BVF Warrants"). As a result of the Beneficial Ownership Cap, 164,837 shares underlying such Warrants are exercisable, which constitutes 6.89% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point Partners, LLC ("Great Point") is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record holder of Warrants to purchase 126,991 shares of Common Stock (the "BOVF Warrants"). As a result of the Beneficial Ownership Cap, 74,057 shares underlying such Warrants are exercisable, which constitutes 3.10% of the shares of Common Stock outstanding, computed in accordance with Rule 13d-3. Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares except to the extent of their respective pecuniary interests Y N See Item 4. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G/A to which this Exhibit is attached, and such SCHEDULE 13G/A is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G/A and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl Great Point Partners, LLC /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Dr. Jeffrey R. Jay, M.D. /s/ Dr. Jeffrey R. Jay, M.D 02/17/2026 Ms. Lillian Nordahl /s/ Ms. Lillian Nordahl 02/17/2026